Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast CancerKirsten A. Nyrop, Hyman B. Muss, Carey K. Anders et al.|The Oncologist|2018Cited by 94
Race, response to chemotherapy, and outcome within clinical breast cancer subtypesJ. R. Tichy, Lisa A. Carey, Allison M. Deal et al.|Breast Cancer Research and Treatment|2015Cited by 61
Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, <i>p16INK4a</i>Shlomit Strulov Shachar, Hyman B. Muss, Allison M. Deal et al.|JNCI Cancer Spectrum|2020Cited by 33
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast CancerAutumn J. McRee, Elizabeth Claire Dees, P. Kelly Marcom et al.|Clinical Breast Cancer|2017Cited by 30
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancerCarey K. Anders, Jonathan S. Serody, Mark G. Woodcock et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 28